Search PubMed⌕ Search

Biomedical subjects

J Prandota

Publications and source records attributed to J Prandota.

At least 73 records · Page 4Linked to original sources
PubMed1982

Urinary elimination kinetics and diuretic effect of intravenous furosemide in nephrotic children.

The pharmacokinetics and pharmacodynamics of furosemide (F) was studied in 8 steroid-responsive nephrotic syndrome (NS) children aged 2.8-6 years with normal renal function and a mean serum albumin concentration of 1.52 +/- (SD) 0.47 g/100 ml. F was given as a single intravenous bolus injection at a dose of 2 mg/kg of actual body weight. The elimination half-life of F calculated from the drug cumulative urinary excretion data was 0.598 +/- 0.24 h. No correlation was found between Ft1/2 and the serum albumin concentration or the age of the patients. The statistically significant diuretic effect of F in the patients lasted 4 h. However, 2 h after F was administered, the children excreted an average of 82.5% of the urine volume collected during significant diuresis. Also, during this time, the patients excreted 57.7% of the given dose of F, which was 96.8% of the drug dose finally excreted in the 24-hour urine collection. This indicates that in some NS children F may be given intravenously more frequently, if necessary, provided that hypovolemia and serum electrolyte depletion resulting from the preceding dose of the drug have been corrected, and the amount of F administered initially was carefully considered.

Child↗
PubMed1980

Effect of tienilic acid (Diflurex) on the binding of warfarin 14C to human plasma proteins.

Tienilic acid (Diflurex), a new diuretic with a chemical structure close to that of ethacrynic acid, displaces significant amounts of warfarin from 2 g/l human albumin in vitro by a competitive mechanism. When physiologic concentrations of human albumin are used, or with human plasma there is no such interaction. Because excessive hypoprothrombinaemia and haemorrhage were reported in vivo when tienilic acid was added to oral coumarin anticoagulant therapy, it is advised to use another diuretic if necessary.

Aged↗
PubMed1980

Binding of erythromycin base to human plasma proteins.

The binding of erythromycin base (EB) to human plasma (HP) proteins was measured by equilibrium dialysis using EB-14C at approximately 0.5 microgram/ml in the plasma phase, expected therapeutic concentration. EB was 64.5 +/- 0.4% (mean +/- S.D.) bound to HP. The percentage of bound EB was linearly related to the logarithm of HP dilution. Physiological concentrations linearly related to the logarithm of HP dilution. Physiological concentrations of human serum albumin (HSA) and a1 acid glycoprotein (a1AGP) bound 8.7 +/- 1.6 and 54.5 +/- 0.6%, respectively, of the drug. No binding of EB to HDL or LDL or human gamma globulins was found. For HSA separately, EB binding followed a non-saturable phenomenon with n'K' = 100 +/- 5, while for a1AGP the binding was following a saturable phenomenon with n" = 1 +/- 0.045, K" = 35,000 +/- 5000 M-1. It can then be shown that, in human plasma, EB is only bound to those two proteins: firstly by computing the binding of EB to HSA and a1AGP with the previously indicated parameters, and secondly by measuring the binding of EB to HP. The computed curve fairly fits to the measured one. Interaction of EB with HP involved hydrophobic, ionic and hydrogen forces. Lower than 37 degrees C temperatures decreased EB binding. Significant competitive binding was demonstrated between EB and acetylsalicylic acid, furosemide, phenylbutazone, warfarin and bilirubin.

Aspirin↗